Parallel Advisors’s Moderna MRNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $327K | Sell |
4,672
-209
| -4% | -$10.8K | 0.01% | 971 |
|
|
2026
Q1 | $248K | Buy |
4,881
+1,537
| +46% | +$71.7K | ﹤0.01% | 1051 |
|
|
2025
Q4 | $98.6K | Sell |
3,344
-1,517
| -31% | -$41.2K | ﹤0.01% | 1476 |
|
|
2025
Q3 | $126K | Buy |
4,861
+343
| +8% | +$9.57K | ﹤0.01% | 1299 |
|
|
2025
Q2 | $125K | Buy |
4,518
+115
| +3% | +$3.03K | ﹤0.01% | 1250 |
|
|
2025
Q1 | $125K | Buy |
4,403
+451
| +11% | +$16K | ﹤0.01% | 1186 |
|
|
2024
Q4 | $164K | Buy |
3,952
+605
| +18% | +$28.9K | ﹤0.01% | 1014 |
|
|
2024
Q3 | $224K | Sell |
3,347
-902
| -21% | -$82.8K | 0.01% | 877 |
|
|
2024
Q2 | $505K | Sell |
4,249
-1,163
| -21% | -$147K | 0.01% | 532 |
|
|
2024
Q1 | $577K | Buy |
5,412
+1,624
| +43% | +$164K | 0.02% | 493 |
|
|
2023
Q4 | $377K | Sell |
3,788
-1,922
| -34% | -$162K | 0.01% | 577 |
|
|
2023
Q3 | $590K | Sell |
5,710
-250
| -4% | -$27.9K | 0.02% | 416 |
|
|
2023
Q2 | $724K | Sell |
5,960
-508
| -8% | -$67.8K | 0.02% | 378 |
|
|
2023
Q1 | $993K | Sell |
6,468
-323
| -5% | -$53.3K | 0.03% | 310 |
|
|
2022
Q4 | $1.22M | Buy |
6,791
+209
| +3% | +$34.2K | 0.05% | 226 |
|
|
2022
Q3 | $778K | Sell |
6,582
-771
| -10% | -$117K | 0.04% | 285 |
|
|
2022
Q2 | $1.05M | Sell |
7,353
-413
| -5% | -$59K | 0.05% | 237 |
|
|
2022
Q1 | $1.36M | Buy |
7,766
+399
| +5% | +$67.2K | 0.05% | 221 |
|
|
2021
Q4 | $1.87M | Buy |
7,367
+1,221
| +20% | +$357K | 0.07% | 182 |
|
|
2021
Q3 | $2.37M | Buy |
6,146
+2,787
| +83% | +$1.03M | 0.1% | 149 |
|
|
2021
Q2 | $789K | Buy |
3,359
+67
| +2% | +$12K | 0.03% | 293 |
|
|
2021
Q1 | $431K | Buy |
3,292
+1,703
| +107% | +$247K | 0.02% | 389 |
|
|
2020
Q4 | $166K | Buy |
1,589
+604
| +61% | +$61.1K | 0.01% | 648 |
|
|
2020
Q3 | $70K | Buy |
985
+287
| +41% | +$20K | ﹤0.01% | 920 |
|
|
2020
Q2 | $44K | Buy |
698
+52
| +8% | +$2.85K | ﹤0.01% | 1093 |
|
|
2020
Q1 | $19K | Sell |
646
-1,496
| -70% | -$34.4K | ﹤0.01% | 1337 |
|
|
2019
Q4 | $42K | Buy |
2,142
+142
| +7% | +$2.52K | ﹤0.01% | 1095 |
|
|
2019
Q3 | $32K | Sell |
2,000
-1,200
| -38% | -$17.7K | ﹤0.01% | 1161 |
|
|
2019
Q2 | $47K | Sell |
3,200
-6,950
| -68% | -$149K | ﹤0.01% | 931 |
|
|
2019
Q1 | $207K | Buy |
+10,150
| New | +$188K | 0.02% | 392 |
|
Other funds holding MRNA
TP
Parallel Advisors's MRNA Position: Q2 2026 in Review
Parallel Advisors reduced its Moderna (MRNA) stake by 4.3% in Q2 2026, selling an estimated $10.8K and leaving 4,672 shares worth $327K. The position accounts for 0.01% of the portfolio, ranked #971.
Parallel Advisors first reported a position in MRNA in Q1 2019 and has held it in 30 quarters since. The position peaked at $2.37M in Q3 2021. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.
- Parallel Advisors held 4,672 shares of Moderna worth $327K as of Q2 2026.
- Parallel Advisors sold 209 Moderna shares in Q2 2026, an estimated $10.8K.
- Moderna made up 0.01% of Parallel Advisors's portfolio in Q2 2026, its #971 holding.
- Parallel Advisors first reported a position in Moderna in Q1 2019 and has held it in 30 quarters since.
- Parallel Advisors's Moderna position peaked at $2.37M in Q3 2021.
- 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.
Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.